目的 探讨长链非编码RNA-MEG3(lncRNA-MEG3)在激素性股骨头坏死中的表达及意义。 方法 应用实时荧光定量PCR方法检测股骨颈骨折患者股骨头组织(30例)和激素性股骨头坏死患者的股骨头及其旁组织(30对)中LncRNA-MEG3的表达并分析其临床意义。 结果 激素性坏死的股骨头骨组织中lncRNA-MEG3的含量最高,其次为其旁组织,股骨颈骨折患者骨组织中含量最低,差异均有统计学意义(P<0.05);两组间患者的性别比例、年龄(<60岁或≥60岁)比例无显著性差异(P>0.05);股骨头坏死组,服用不同种类激素(甲泼尼龙、地塞米松)的患者间lncRNA-MEG3含量无显著差别(P>0.05);在不同ARCO分期(III期或IV期)患者中,IV期lncRNA-MEG3相对表达量明显高于III期(P<0.05)。 结论 长链非编码RNA-MEG3的表达与激素性股骨头坏死关系密切,且它的表达与激素性股骨头坏死的ARCO分期相关。
Abstract
Objective To investigate the expression and significance of long non-coding RNA-MEG3(lncRNA-MEG3) in steroid-induced femoral head necrosis. Methods Real-time fluorescence quantitative PCR was used to detect the expression of lncRNA-MEG3 in femoral head tissues of patients with femoral neck fracture (30 cases) and femoral head and its adjacent tissues of patients with steroid-induced femoral head necrosis (30 pairs), and its clinical significance was analyzed. Results The content of lncRNA-MEG3 was the highest in the femoral head bone tissues with steroid-induced necrosis, its adjacent tissues was followed, and the lowest was the bone tissues of patients with femoral neck fracture, the difference was statistically significant (P<0.05). There was no significant difference in the ratio of gender and age(less than 60 years old or more than 60 years old) between the two groups(P>0.05). In the femoral head necrosis group, there was no significant difference in lncRNA-MEG3 content among patients taking different hormone types (meprednisone or dexamethasone) (P>0.05). In patients with different ARCO stages (stage Ⅲ orⅣ), the relative expression of lncRNA-MEG3 in stage IV was higher that of stage Ⅲ (P<0.05). Conclusions The expression of long non-coding RNA-MEG3 is closely related to steroid-induced femoral head necrosis, and its expression is related to ARCO stage of steroid-induced femoral head necrosis.
关键词
长链非编码RNA;  /
  /
MEG3;  /
  /
股骨头坏死;  /
  /
激素
Key words
Long non-coding RNA;  /
  /
MEG3;  /
  /
Femoral head necrosis;  /
  /
Hormone
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 梁大伟, 杨琼, 裴佳, 等. 478例股骨头坏死患者流行病学调查研究[J]. 临床骨科杂志, 2020, 23(5): 699-702. DOI: 10.3969/j.issn.1008-0287.2020.05.033.
[2] Wu X, Sun W, Tan M. Noncoding RNAs in steroid-induced osteonecrosis of the femoral head[J]. Biomed Res Int, 2019, 2019: 8140595. DOI: 10.1155/2019/8140595.
[3] Zhao DW, Zhang F, Wang BJ, et al. Guidelines for clinical diagnosis and treatment of osteonecrosis of the femoral head in adults (2019 version)[J]. J Orthop Translat, 2020, 21: 100-110. DOI: 10.1016/j.jot.2019.12.004.
[4] 段毅, 易谭勇, 朱乐全, 等. LncRNA MEG3调控miR-328影响类风湿性关节炎滑膜细胞增殖、凋亡和炎性反应[J]. 中国组织化学与细胞化学杂志, 2021, 30(2): 136-145. DOI: 10.16705/j.cnki.1004-1850.2021.02.004.
[5] Chang C, Greenspan A, Gershwin ME. The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis[J]. J Autoimmun, 2020, 110: 102460. DOI: 10.1016/j.jaut.2020.102460.
[6] Zhao XY, Lin JD. Long noncoding RNAs: a new regulatory code in metabolic control[J]. Trends Biochem Sci, 2015, 40(10): 586-596. DOI: 10.1016/j.tibs.2015.08.002.
[7] Choudhry H, Harris AL, McIntyre A. The tumour hypoxia induced non-coding transcriptome[J]. Mol Aspects Med, 2016, (47-48): 35-53. DOI: 10.1016/j.mam.2016.01.003.
[8] Briggs JA, Wolvetang EJ, Mattick JS, et al. Mechanisms of long non-coding RNAs in mammalian nervous system development, plasticity, disease, and evolution[J]. Neuron, 2015, 88(5): 861-877. DOI: 10.1016/j.neuron.2015.09.045.
[9] Yan HL, Yuan JP, Gao LK, et al. Long noncoding RNA LncRNA-MEG3 activation of p53 mediates ischemic neuronal death in stroke[J]. Neuroscience, 2016, 337: 191-199. DOI: 10.1016/j.neuroscience. 2016. 09.017.
[10] 张轩铭, 吕松岑. 长链非编码RNA LncRNA-MEG3对成骨分化及骨性疾病影响的研究进展[J].实用骨科杂志, 2021, 27(2), 148-152. DOI: 10.13795/j.cnki.sgkz.2021.02.011.
[11] 赵轶男, 袁志, 毕龙, 等. LncRNA LncRNA-MEG3通过抑制Wnt/β-catenin信号通路对骨关节炎软骨细胞增殖和凋亡的影响[J]. 现代生物医学进展, 2019, 19(24): 27-33. DOI: 10.13241/j.cnki.pmb. 2019.24. 004.
[12] Wang GQ, Ye QW, Ning SJ, et al. LncRNA LncRNA-MEG3 promotes endoplasmic reticulum stress and suppresses proliferation and invasion of colorectal carcinoma cells through the LncRNA-MEG3/miR-103a-3p/PDHB ceRNA pathway[J]. Neoplasma, 2021, 68(2): 362-374. DOI: 10.4149/neo_2020_200813N858.
[13] Qiu GZ, Tian W, Fu HT, et al. Long noncoding RNA-LncRNA-MEG3 is involved in diabetes mellitus-related microvascular dysfunction[J]. Biochem Biophys Res Commun, 2016, 471(1): 135-141. DOI: 10.1016/j.bbrc.2016.01.164.
[14] Wallace C, Smyth DJ, Maisuria-Armer M, et al. The imprinted DLK1-LncRNA-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes[J]. Nat Genet, 2010, 42(1): 68-71. DOI: 10.1038/ng.493.
[15] Chen RP, Huang ZL, Liu LX, et al. Involvement of endoplasmic reticulum stress and p53 in lncRNA LncRNA-MEG3-induced human hepatoma HepG2 cell apoptosis[J]. Oncol Rep, 2016, 36(3): 1649-1657. DOI: 10.3892/or.2016.4919.
[16] Xia Y, He ZC, Liu B, et al. Downregulation of LncRNA-MEG3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/beta-catenin signaling pathway[J]. Mole Med Rep, 2015, 12(3): 4530-4537. DOI: 10.3892/mmr.2015.3897.
[17] Teng GY, Wang YJ, Geng M, et al. LncRNA MEG3 inhibits the growth, invasion and migration of Wilms' tumor via Wnt/β-catenin pathway[J]. Eur Rev Med Pharmacol Sci, 2020, 24(19): 9899-9907. DOI: 10.26355/eurrev_202010_23200.
[18]姚金池, 杨春露, 车敏, 等. LncRNA MEG3在骨肉瘤组织中的表达及对MG-63细胞增殖、凋亡与侵袭的影响[J]. 解剖科学进展, 2020, 26(2): 150-153. DOI: 10.16695/j.cnki.1006-2947.2020.02.008.
基金
浙江省大学生科技创新活动计划(新苗人才计划)资助(2020R413006);浙江省医药卫生科技计划(2021KY206);温州市公益性科技计划(Y20190267)